Yip D, Zalcberg J, Blay JY, Eriksson M, Espinoza D, Price T, Marreaud S, Italiano A, Steeghs N, Boye K, Underhill C, Gebski V, Simes J, Gelderblom H, Joensuu H (2025)
Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial
Br J Cancer (in press)
DOI 10.1038/s41416-025-02983-w, PubMed 40133509

Berner K, Hernes E, Kvassheim M, Revheim ME, Bastiansen J, Selboe S, Bakken CL, Grønningsæter SR, Bruland ØS, Larsen RH, Bouzelmat L, Jardine VL, Stokke C (2025)
First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen-Targeted ²¹²Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer
J Nucl Med (in press)
DOI 10.2967/jnumed.124.269299, PubMed 40081958

Ullmann Miller J, Fauske L, Sigurdardottir S, Arfa S, von der Lippe C (2025)
'In the dark': parents' lifelong commitment to supporting children with Bardet-Biedl syndrome
Health Psychol Behav Med, 13 (1), 2467432
DOI 10.1080/21642850.2025.2467432, PubMed 39968158